A comprehensive view of Oral Medicines/Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
FDA approves GSKs oral Jesduvroq daprodustat to treat anemia caused by chronic kidney disease in adults who have received dialysis for at least four months; CKD affect about 700 million patients worldwide, with one in seven developing anemia
Published:
February 03, 2023
by GSK Group (GlaxoSmithKline)
|
Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis
Published:
January 31, 2023
by PR Newswire
|
Health Canada approves Apex Labs’ take home psilocybin clinical trial; study to evaluate efficacy, safety, tolerability of APEX-52, a microdose, oral synthetic psilocybin drug product to treat depression, anxiety in adults diagnosed with PTSD
Published:
January 19, 2023
by Canada Newswire
|
Dr. Reddy's acquires trademark rights from Pfizer for Primcyv breast cancer drug as an oral capsule in India; Dr. Reddy's to manufacture Primcyv’s active pharmaceutical ingredient and finished drug at its FDA-approved state-of-the-art facilities
Published:
January 16, 2023
by BioSpectrum India
|
Novo Nordisk announces FDA approval of label update for Rybelsus allowing use as a first-line option for adults with type 2 diabetes
Published:
January 13, 2023
by ENP Newswire
|
Ask us about our Government & Public Policy market view
Trending Chart
Interactive chart with headline count